Thailand's FDA Registers Generic Version Of Abbott's Antiretroviral Aluvia For Use Under Compulsory Licensing Program
Main Category: HIV / AIDSAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 18 Oct 2007 - 12:00 PDT
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
5 (2 votes) |
Thailand's Food and Drug Administration on Tuesday completed the registration of a generic version of Abbott Laboratories' antiretroviral drug Aluvia for use under the country's compulsory licensing program, the Bangkok Post reports. The generic version is manufactured by Indian pharmaceutical company Matrix Laboratories (Apiradee, Bangkok Post, 10/17). The Thai Ministry of Public Health in June confirmed that it would continue with its plan to issue a compulsory license for the drug after Abbott and the health ministry could not reach a price agreement during negotiations.
The Thai government in January issued a compulsory license to produce a lower-cost version of Abbott's Kaletra. The drug company in May offered to sell Aluvia, an updated version of Kaletra, at a reduced price in Thailand on the condition that the country agreed not to allow generic versions of the drug into the market, Siriwat Thiptaradol, secretary-general of the Thai FDA, said. Abbott offered to sell Aluvia for about 34,000 baht, or $1,000, per person annually. Matrix offered to sell a generic version of Aluvia to Thailand for 24,324 baht, or $695, per person annually (Kaiser Daily HIV/AIDS Report, 6/7).
Vichai Chokewiwat, chair of the Government Pharmaceutical Organization and the health ministry's Committee on Compulsory Licensing, said GPO soon will import the first shipment of the generic version of Aluvia from Matrix. According to Siriwat, the registration process took more than three months to complete. The shipment from Matrix will include enough doses of the drug for 8,000 people during the next six months, the Post reports (Bangkok Post, 10/17).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our hiv / aids section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/85893.php>
APA
http://www.medicalnewstoday.com/releases/85893.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




